May 3rd 2024
During a Case-Based Roundtable® event, Ruth M. O'Regan, MD, led a discussion on whether to order next-generation sequencing and/or circulating tumor DNA testing for a patient with hormone receptor–positive breast cancer after progression in the first article of a 2-part series.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Show Me Your Care Plan: Nursing Considerations for Managing Breast Cancer Patients
View More
Community Practice Connections™: The Newest Frontier in HR+ Breast Cancer—Targeting ESR1 Mutations with Next-Generation Endocrine Therapy
View More
Clinical Case Vignette Series™: 40th Annual Miami Breast Cancer Conference®
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
HER2+ Breast Cancer Tumor Board: Navigating Current and Evolving Strategies from Early Stages to Metastases
View More
Show Me the Data®: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
23rd Annual International Congress on the Future of Breast Cancer® West
July 12-13, 2024
Register Now!
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Community Practice Connections®: Evaluating the Evolving Treatment Landscape for mHR+ Breast Cancer-How to Personalize Care and Improve Patient Outcomes
View More
Community Practice Connections™: Leveraging Multidisciplinary Teams in Early-Stage Breast Cancer When the Goal Is Cure
View More
Community Practice Connections™: 22nd Annual International Congress on the Future of Breast Cancer®
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
22nd Annual School of Breast Oncology
November 7-9, 2024
Register Now!
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
HER2 in Esophagogastric Adenocarcinoma
October 24th 2013Determination of HER2 status has become an important part of the workup of patients with advanced esophagogastric cancer, given recent data from a phase III trial (ToGA) indicating that trastuzumab, an anti-HER2 monoclonal antibody, prolongs survival in these patients.
Read More
PFS as an Endpoint in Ovarian Cancer Trials
October 23rd 2013James "Tate" T. Thigpen, MD, professor of medicine, director of medical oncology, University of Mississippi School of Medicine, discusses overall survival (OS) and progression-free survival (PFS) as endpoints in ovarian cancer trials.
Watch
Certain Patients May Benefit More From Eribulin
September 27th 2013A subgroup analysis showed that certain patients with breast cancer may benefit more from eribulin, and quality of life (QoL) data suggest that patients may prefer eribulin because of a lower frequency of certain adverse events.
Read More
Potential Therapeutic Targets and Molecular Drivers of Inflammatory Breast Cancer
September 24th 2013Komal L. Jhaveri, MD, Assistant Professor, Department of Medicine, NYU Langone Medical Center, discusses the background and results of a study looking at crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC).
Watch
Mechanism of Action: Fulvestrant (Faslodex)
September 23rd 2013It has long been recognized that many breast tumors in postmenopausal women are hormone-dependent and that hormonal manipulation can alter the natural history of the disease. Learn more about the mechanism of action of fulvestrant (Faslodex).
Read More
New Approaches to ER+ Breast Cancer
September 23rd 2013New approaches to treating women with advanced ER+ breast cancer are in development, which includes both hormone therapy and combinations with targeted agents. The continuing goal is to understand disease biology and individualize treatment regimens to increase survival.
Read More
TNBC Studies Yield Clues for Future Directions
September 20th 2013Researchers are still at the drawing board when it comes to finding revolutionary solutions for the treatment of triple-negative breast cancer (TNBC), but recent studies have shed light on the diversity of the disease and offered hints about the directions future inquiries should take.
Read More
ODAC Suggests Approval of Neoadjuvant Pertuzumab Regimen
September 13th 2013The FDA’s Oncologic Drugs Advisory Committee voted 13-0 with one abstention in support of pertuzumab (Perjeta) in combination with trastuzumab and docetaxel for patients with HER2-positive breast cancer in the neoadjuvant setting.
Read More